RB1 and prostate adenocarcinoma: The Cancer Genome Atlas (TCGA) data suggest UHRF1 is significantly overexpressed in malignancies that frequently present RB pathway inactivation including sarcomas, breast invasive carcinomas, and lung adenocarcinomas, but not in cancers where RB1 loss is infrequent, like prostate adenocarcinomas (Supplementary Fig. 1A) [17].